Add to ORKGRahul Chandra, Harneel Saini, Russell Cerejo, Ashis Tayal, Konark Malhotra Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USACorrespondence: Konark MalhotraDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USATel +1- 412-359-8841Fax +1- 412-442-2115Email konark.malhotra@yahoo.comAbstract: Antiplatelet medications are the mainstay for secondary stroke treatment. Aspirin, clopidogrel, and aspirin-dipyridamole are commonly used antiplatelet medications. Other antiplatelet medications such as ticagrelor and prasugrel have been majorly used in cardiovascular or neuro-interventional specialties. Recent studies have paved a way to their use in secondary stroke prevention. In this review, we have briefly discuss...
The article is a review of literature on antiplatelet (antiagregant) therapy in the secondary preven...
Stroke is an acute neuro-deficit disease that occurs when there is a disturbance of cerebral blood f...
Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review ...
The purpose of this article is to review the effectiveness and safety of ticagrelor in the preventio...
Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These pat...
Objective: A literature review of antiplatelet agents for primary and secondary stroke prevention, i...
Importance: Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic strok...
Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These pat...
BACKGROUND Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention o...
International audienceTicagrelor may be a more effective antiplatelet therapy than aspirin for the p...
Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke ...
IntroductionPatients with minor ischemic stroke or transient ischemic attack represent a high-risk p...
Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setti...
Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity...
The article is a review of literature on antiplatelet (antiagregant) therapy in the secondary preven...
Stroke is an acute neuro-deficit disease that occurs when there is a disturbance of cerebral blood f...
Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review ...
The purpose of this article is to review the effectiveness and safety of ticagrelor in the preventio...
Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These pat...
Objective: A literature review of antiplatelet agents for primary and secondary stroke prevention, i...
Importance: Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic strok...
Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These pat...
BACKGROUND Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention o...
International audienceTicagrelor may be a more effective antiplatelet therapy than aspirin for the p...
Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke ...
IntroductionPatients with minor ischemic stroke or transient ischemic attack represent a high-risk p...
Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setti...
Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity...
The article is a review of literature on antiplatelet (antiagregant) therapy in the secondary preven...
Stroke is an acute neuro-deficit disease that occurs when there is a disturbance of cerebral blood f...
Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review ...